RTI Surgical Holdings Inc

RTI Surgical — RTI Biologics — Merger or Acquisition (June 2013)

16 slides from RTI Surgical's merger presentation, Jun 12, 2013

  1. Slide 1: Acquisition of Pioneer Surgical Technology

    Investor Presentation June 12, 2013 Exhibit 99.3 Acquisition of Pioneer ® Surgical Technology

  2. Slide 2: Forward Looking Statement

    2 Forward Looking Statement This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management

  3. Slide 3: Transaction Summary

    Acquisition Purchase Price Financial Impact Financing Additional Information 3 Transaction Summary RTI is acquiring Pioneer ® Surgical Technology, a leading medical technology company that manufactures and distributes synthetic and metal products in the orthopedics, biologics, spine, trauma and card

  4. Slide 4: Debt & Equity Financing

    4 Debt Preferred Equity Debt & Equity Financing TD Bank, N.A. and Regions Bank 5 year, $80 million senior secured credit facility – $20 million revolver – $60 million Term Loan A – Cost of credit facility equal to LIBOR plus 100 – 175 bps, based on senior debt to EBITDA ratio Water Street Healthcare

  5. Slide 5: Water Street Healthcare Partners

    5 Water Street Healthcare Partners Strategic private equity firm focused exclusively on healthcare industry Strong track record of leading transformational acquisitions that have created market-leading healthcare companies of greater long-term value Expertise in integrating businesses to achieve syn

  6. Slide 6: RTI's Acquisition of Pioneer Creates a Diversified Global Surgical Implant Company

    6 RTI’S ACQUISITION OF PIONEER ® CREATES A DIVERSIFIED GLOBAL SURGICAL IMPLANT COMPANY POSITIONED FOR GROWTH IN ORTHOPEDICS AND BIOLOGICS Strategic Rationale Diversification of Implant Portfolio – Expands current allograft and xenograft biologics portfolio with metal and synthetic implants – Adds at

  7. Slide 7: Pioneer Surgical Technology Overview

    7 Pioneer ® Surgical Technology Overview Leading manufacturer of synthetic and metal products in the Orthopedics, Biologics, Spine, Trauma and Cardiothoracic markets Founded in 1992 Headquartered in Marquette, MI with international headquarters in Houten, The Netherlands Two manufacturing facilities

  8. Slide 8: Pioneer Surgical Technology Revenue 2012 Historical

    2012 HISTORICAL 8 Pioneer ® Surgical Technology Revenue (Dollars in Millions) Cardiothoracic Spine 50% Trauma 30% Biologics 15% 5% $70 $77 $88 $40 $60 $80 $100 2010 2011 2012

  9. Slide 9: Pioneer Business Segments

    SPINE TRAUMA BIOLOGICS CARDIOTHORACIC 9 Pioneer ® Business Segments Broad product portfolio Cervical Thoracolumbar Lateral Minimally Invasive Surgery Cable system Cannulated screws Diversified implant offering Leading sternal cable system Plating system o Plate systems o PEEK interbody fusion o PEEK

  10. Slide 10: Combined Company Overview

    10 Combined Company Overview

  11. Slide 11: Addition of Synthetics & Metals

    11 32% 68% $147 $166 $175 $263 $- $50 $100 $150 $200 $250 $300 RTI 2008 RTI 2010 RTI LTM 3/31/13 Pro Forma LTM 3/31/13 Allograft & Xenograft Synthetic / Metal Addition of Synthetics & Metals (Dollars in Millions)

  12. Slide 12: Expanding Direct Distribution

    12 Expanding Direct Distribution 33% 37% 39% 47% 0% 10% 20% 30% 40% 50% RTI 2008 RTI 2010 RTI LTM 3/31/13 Pro Forma LTM 3/31/13 (Direct Revenue as a percentage of Total Revenue)

  13. Slide 13: Enhance International Platform

    13 Enhance International Platform Combined companies will offer products in 47 countries Combined European distribution platform: – Neunkirchen, Germany – Houten, The Netherlands Growing China distribution footprint

  14. Slide 14: Combined Operations

    14 LTM March 31, 2013 RTI PIONEER Combined Operations Provides immediate scale Strong growth profile Enhances RTI’s margin profile COMBINED Revenue $ $ $ Gross Profit $ $ $ Margin 48% 70% 56% EBITDA $ $ $ Margin 11% 15% 12% (Dollars in Millions)

  15. Slide 15: Advances RTI's Strategic Goals

    15 ADVANCES RTI’S STRATEGIC GOALS Summary DIVERSIFIES PORTFOLIO/ REVENUE / CUSTOMER BASE BRINGS STRONG GROWTH OPPORTUNITIES LEVERAGES EXPERTISE OF PREMIER HEALTHCARE- FOCUSED EQUITY INVESTOR

  16. Slide 16: RTI Biologics Inc.

    RTI Biologics Inc. NASDAQ: RTIX www.rtix.com

RTI Biologics — Merger or Acquisition (June 2013) on 6ix